Bio-Path Holdings Inc (BPTH)
0.871
-0.03
(-3.18%)
USD |
NASDAQ |
Oct 04, 16:00
0.8996
+0.03
(+3.28%)
After-Hours: 20:00
Bio-Path Holdings SG&A Expense (Annual): 4.235M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.235M |
| December 31, 2022 | 4.736M |
| December 31, 2021 | 4.533M |
| December 31, 2020 | 4.33M |
| December 31, 2019 | 4.108M |
| December 31, 2018 | 3.379M |
| December 31, 2017 | 3.523M |
| December 31, 2016 | 3.014M |
| December 31, 2015 | 2.465M |
| December 31, 2014 | 2.715M |
| Date | Value |
|---|---|
| December 31, 2013 | 1.635M |
| December 31, 2012 | 0.9861M |
| December 31, 2011 | 1.225M |
| December 31, 2010 | 1.127M |
| December 31, 2009 | 0.721M |
| December 31, 2008 | 2.388M |
| June 30, 2007 | 0.1074M |
| June 30, 2006 | 0.1413M |
| June 30, 2005 | 0.0825M |
| June 30, 2004 | 0.0782M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.108M
Minimum
2019
4.736M
Maximum
2022
4.388M
Average
4.33M
Median
2020
SG&A Expense (Annual) Benchmarks
| Aadi Bioscience Inc | 44.55M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |
| iBio Inc | 11.67M |
| Theriva Biologics Inc | 7.12M |